首页> International journal of gynecological cancer : official journal of the International Gynecological Cancer Society> CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer.

CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Ingrid,Boere

第一单位： Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands i.boere@erasmusmc.nl.

作者： Ingrid,Boere ^[1] ; Ignace,Vergote ^[2] ; Rob,Hanssen ^[3] ; Mathilde,Jalving ^[4] ; Christine,Gennigens ^[5] ; Petronella,Ottevanger ^[6] ; Yes J,van de Wouw ^[7] ; Cristianne J F,Rijcken ^[3] ; Ron H J,Mathijssen ^[8] ; Jonathan,Ledermann ^[9]

作者单位： Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands i.boere@erasmusmc.nl. ^[1] Division of Gynaecological Oncology, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium. ^[2] Cristal Therapeutics, Maastricht, The Netherlands. ^[3] Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ^[4] Department of Medical Oncology, CHU de Liège, Liège, Belgium. ^[5] Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands. ^[6] Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands. ^[7] Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. ^[8] Department of Oncology, University College London (UCL) Cancer Institute, UCL & UCL Hospitals Comprehensive Biomedical Research Centre, London, UK. ^[9]

关键词 Cystadenocarcinoma, Serous Ovarian Cancer